- Home
- NBBK vs ZYME Comparison
NBBK vs ZYME Comparison
Compare NBBK & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- ZYME
- Stock Information
- Founded
- NBBK 1892
- ZYME 2003
- Country
- NBBK United States
- ZYME United States
- Employees
- NBBK N/A
- ZYME N/A
- Industry
- NBBK
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- ZYME Health Care
- Exchange
- NBBK Nasdaq
- ZYME Nasdaq
- Market Cap
- NBBK 783.2M
- ZYME 751.6M
- IPO Year
- NBBK N/A
- ZYME 2017
- Fundamental
- Price
- NBBK $20.32
- ZYME $13.72
- Analyst Decision
- NBBK Buy
- ZYME Buy
- Analyst Count
- NBBK 1
- ZYME 5
- Target Price
- NBBK $22.00
- ZYME $19.00
- AVG Volume (30 Days)
- NBBK 160.3K
- ZYME 558.9K
- Earning Date
- NBBK 10-30-2024
- ZYME 10-31-2024
- Dividend Yield
- NBBK N/A
- ZYME N/A
- EPS Growth
- NBBK N/A
- ZYME N/A
- EPS
- NBBK 0.30
- ZYME N/A
- Revenue
- NBBK $146,994,000.00
- ZYME $62,199,000.00
- Revenue This Year
- NBBK N/A
- ZYME $30.09
- Revenue Next Year
- NBBK N/A
- ZYME N/A
- P/E Ratio
- NBBK $67.20
- ZYME N/A
- Revenue Growth
- NBBK 11.94
- ZYME N/A
- 52 Week Low
- NBBK $13.10
- ZYME $7.97
- 52 Week High
- NBBK $20.98
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- NBBK 58.58
- ZYME 45.89
- Support Level
- NBBK $19.51
- ZYME $12.39
- Resistance Level
- NBBK $20.97
- ZYME $17.70
- Average True Range (ATR)
- NBBK 0.54
- ZYME 0.82
- MACD
- NBBK -0.04
- ZYME -0.27
- Stochastic Oscillator
- NBBK 65.76
- ZYME 24.61
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.